Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(21/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(21/week)
News
United States
(578/week)
Manufacturing
(398/week)
Energy
(304/week)
Technology
(413/week)
Environment
(238/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Blueprint Medicines Corporation
Jun 29, 2020
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT(TM) (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST
Jun 06, 2020
Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Disease Symptoms in Patients with Indolent Systemic Mastocytosis
Jun 03, 2020
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 29, 2020
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors
May 27, 2020
Blueprint Medicines to Present at Upcoming Investors Conferences
May 26, 2020
Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday, May 29, 2020
May 15, 2020
Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
May 14, 2020
Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing RET-Altered Cancer and Systemic Mastocytosis Programs
Apr 28, 2020
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
Mar 16, 2020
Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis
Mar 09, 2020
Blueprint Medicines to Report Updated Data from the Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis on Monday, March 16, 2020
Feb 24, 2020
Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 2020 AAAAI Annual Meeting
Feb 06, 2020
Blueprint Medicines to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020
Jan 22, 2020
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
Jan 17, 2020
PANTHERx® Rare Pharmacy Selected by Blueprint Medicines Corporation to Distribute AYVAKIT(TM) (avapritinib) for Genomically Defined Patient Population with Rare Cancer, GIST
Jan 13, 2020
Blueprint Medicines Announces 2020 Corporate Goals
Jan 09, 2020
Blueprint Medicines Announces FDA Approval of AYVAKIT(TM) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
Jan 08, 2020
Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer
Jan 06, 2020
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
Dec 08, 2019
Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested
‹‹
Page 2
››
Latest News
Apr 25, 2024
Universal Robots announces seamless integration with Siemens PLCs
Apr 25, 2024
Stak Mobility to Launch Second Mobility Hub in Pittsburgh; Sees Continued Momentum Across the US
Apr 25, 2024
DIC Algae Oil Sulfurized Extreme Pressure Additives Present Promising Alternatives to Lard Oils and Vegetable...
Apr 25, 2024
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment...
Apr 25, 2024
Ranpak to Hold Conference Call to Discuss First Quarter 2024 Results
Apr 25, 2024
Nodal Exchange Announces Cooperation with Deutsche Börse Market Data + Services
Apr 25, 2024
Corporate Funding for Energy Storage Sector Totaled $11.7 Billion in Q1 2024
Apr 25, 2024
Empowering Innovation: StatLab Welcomes Scientific Device Laboratory Into Family
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events